Actually I think the dilution got out of hand briefly 12-18 months ago on a single restricted share lot at .025 for $245,000 (apx, IIRC, or was it $750,000? I forget), but since then the restricted new share prices had rallied according to the 10-Q's. I suspect CABN has 3-6 months of cash on hand, so I do not expect serious new restricted share sale new dilution next, but without surprise news (which I never discount, by holding a share core all the time) I expect we may finally see .025 retail in the next 3 months. We might also see .10 before we see .025 as well. I have my core holding, and orders for .025 to .045 in place now.
CABN, thanks to prior Byron press work has all the public exposure it needs or will need for a good while now. It is down to the two chemical engineers to complete the tests and new ideas think tank work to get something finalized the market will buy. I think the current potential buyers are already watching. They have the right idea, the right team players, the right market and the right people watching. Only one last peg needs to fall into place for this to rock and roll, so yes, if they pull it off, the buying op of a life time is straight ahead.
I am not as concerned about the last PR on the patentability of the latest catalyst as others are, as potential customers will need the other tech (which is patent pending by CABN, the CO2 to methanol step), and people to put this all together,so a pilot plant deal with CABN support and CABN control of new patents that might come out of the pilot plant tweaking is still all possible IMHO. The trick is to keep the patent mill running, till a first pilot plant deal arrives.
Market Data 
Markets 
AI
